只使用免费官方源：SEC Forms 3/4/5 结构化内部人申报，以及 FINRA Consolidated NMS 场外卖空成交量。 两类数据均保留来源边界，不转写成买卖建议。
SEC 已完成季度 Forms 3/4/5 结构化历史基线 + EDGAR 当前季度 Form 4 增量；个股卡片仅展示当前自然季度的非衍生证券买卖代码 P/S（公开市场或私下交易），成交金额由股数 × 每股价格计算。
官方数据说明| 2026-06-15 2026-06-26 | STVN Stevanato Group S.p.A. | Flynn Karen Director | 卖出（S） | 1,493 | US$17.09 | US$25,515.37 | 5,757 | SEC |
| 2026-06-15 2026-06-26 | STVN Stevanato Group S.p.A. | MOREL DONALD E JR Director | 卖出（S） | 1,493 | US$17.09 | US$25,515.37 | 37,424 | SEC |
| 2026-06-15 2026-06-26 | STVN Stevanato Group S.p.A. | Balachandran Madhavan Director | 卖出（S） | 1,493 | US$17.09 | US$25,515.37 | 69,458 | SEC |
| 2026-06-11 2026-06-16 | TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | Kalif Eliyahu Sharon Officer · EVP, Chief Financial Officer | 卖出（S） | 106,563 | US$34.10 | US$363.38万 | 65,621 | SEC |
| 2026-06-05 2026-06-08 | TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | Francis Richard D Officer · President and CEO | 卖出（S） | 6,153 | US$34.35 | US$211,355.55 | 1,177,529 | SEC |
| 2026-06-03 2026-06-04 | TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | Shields Matthew Officer · EVP, Global Operations | 卖出（S） | 16,195 | US$32.87 | US$532,329.65 | 9,989 | SEC |
| 2026-05-14 2026-05-18 | TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | Kalif Eliyahu Sharon Officer · EVP, Chief Financial Officer | 卖出（S） | 153,251 | US$35.61 | US$545.73万 | 172,184 | SEC |
| 2026-05-14 2026-05-18 | TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | Lippman Evan Officer · EVP, Business Development | 卖出（S） | 5,746 | US$35.58 | US$204,442.68 | 6,095 | SEC |
| 2026-05-14 2026-05-18 | TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | Lippman Evan Officer · EVP, Business Development | 卖出（S） | 35,912 | US$35.58 | US$127.77万 | 44,191 | SEC |
| 2026-05-06 2026-05-07 | TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | Weiss Amir Officer · Chief Accounting Officer | 卖出（S） | 10,679 | US$36.00 | US$384,444.00 | 20,016 | SEC |
| 2026-05-05 2026-05-07 | TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard Officer · EVP, Europe Commercial | 卖出（S） | 30,000 | US$35.40 | US$106.2万 | 55,755 | SEC |
| 2026-05-01 2026-05-04 | TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | Sabag Mark Officer · "See ""Remarks""" | 卖出（S） | 144,180 | US$34.99 | US$504.49万 | 80,760 | SEC |
| 2026-04-30 2026-05-04 | TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | Fox Christine Officer · EVP, U.S. Commercial | 卖出（S） | 21,258 | US$35.31 | US$750,619.98 | 63,647 | SEC |
| 代码 | 卖空成交量 | 豁免卖空量 | 场外总成交量 | 卖空量占比 | 报告设施 |
|---|---|---|---|---|---|
| TEVA | 1,114,406.6651 | 2,368 | 1,834,825.3614 | 60.74% | B, Q, N |